Baeten D, Sieper J, Braun J, et al; MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534-2548.
Baraliakos X, Deodhar A. Unanswered questions in the management of axial spondyloarthritis: an opinion piece. Clin Rheumatol. 2014;33:1359-1365.
Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1:e000053.
Braun J, Deodhar A, Dijkmans B, et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59:1270-1278.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379-1390.
Danve A, Reddy A, Vakil-Gilani K, et al. Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis. Clin Rheum 2015;34:117-124.
Davis JC Jr, Van Der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230-3236.
De Bruin F, de Koning A, van den Berg R, et al. Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. Ann Rheum Dis. 2018;77:371-377.
Deodhar A, Poddubnyy D, Pacheco-Tena C, et al; COAST-W Study Group. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71:599-611.
Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2020. doi: 10.1002/art.41477 [Epub ahead of print]
Deodhar A, Gensler LS, Kay J, et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71:1101-1111.
Deodhar A, Reveille JD, Harrison DD, et al. Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol. 2018;45:341-348.
Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2020;72(suppl 10): Abstract L11.
Deodhar A, van der Heijde D, Gensler LS, et al; COAST-X Study Group. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomized, placebo-controlled trial. Lancet. 2020;395:53-64.
Deodhar A, van der Heijde D, Sieper J, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a randomized, double-blind, placebo-controlled study with open-label extension. American College of Rheumatology Convergence. November 5-9, 2020. Oral Presentation 5M015.
Dubreuil M, Sieper J. Editorial: Inflammatory back pain and axial spondyloarthritis: lessons for clinical practice and epidemiologic research. Arthritis Rheumatol. 2018;70:981-983.
Inman RD, Davis JC Jr, Heijde Dv, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402-3412.
Kataria RK, Brent LH. Spondyloarthropathies. Am Fam Physician. 2004;69:2853-2860.
Khmelinskii N, Regel A, Baraliakos X. The role of imaging in diagnosing axial spondyloarthritis. Front Med (Lausanne). 2018;5:106.
Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39-47.
Lorenzin M, Ometto F, Ortolan A, et al. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis. 2020;12:1759720X20934277.
Magrey M, Ritchlin C. Measuring outcomes in ankylosing spondylitis: pearls and pitfalls. Curr Opin Rheumatol. 2019;31:109-117.
Magrey MN, Danve AS, Ermann J, et al. Recognizing axial spondyloarthritis: a guide for primary care. Mayo Clin Proc. 2020;95:2499-2508.
Marona J, Sepriano A, Rodrigues-Manica S, et al. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. RMD Open. 2020;6:e001145.
Mercieca C, van der Horst-Bruinsma IE, Borg AA. Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice. Curr Rheumatol Rep. 2014;16:434.
Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum. 2020; 42:2220-2230.
Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol 2020;32:1432-1439.
Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci. 2013;345:431-436.
Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018;20:35.
Sieper J, van der Heijde D. Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65:543-551.
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73-84.
Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016:374:2563-2574.
van den Berg R, de Hooge M, Rudwaleit M, et al. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Ann Rheum Dis. 2013;72:1646-1653.
van der Heijde D, Lie E, Kvien TK, et al; Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811-1818.
van der Heijde D, Kivitz A, Schiff MH, et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136-2146.
van der Heijde D, Cheng-Chung Wei J, Dougados M, et al; COAST-V study group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441-2451.
van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2378-2387.
van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralization of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomized, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79:595-604.
Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71:1285-1299.
Weisman MH, Witter JP, Reveille JD. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10. Ann Rheum Dis. 2013;72:369-373.

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Atul Deodhar, MD

Professor of Medicine
Medical Director
Rheumatology Clinics
Immunology Infusion Center
Oregon Health & Science University
Portland, Oregon

Disclosures

Disclosure: Atul Deodhar, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Amgen; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Galapagos; Gilead; Janssen; Lilly; Novartis; Pfizer; UCB Pharma
Served as a speaker or a member of a speakers bureau for: Janssen; Novartis; Pfizer; UCB Pharma
Received grants for clinical research from: AbbVie; Boehringer Ingelheim; Galapagos; Gilead; Lilly; Novartis; Pfizer; UCB Pharma

Editor

Karen Badal, MD, MPH

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Karen Badal, MD, MPH, has disclosed the following relevant financial relationships:
Owns stock, stock options or bonds from: Kallyope, Inc.

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

What's New in Axial Spondyloarthritis?

Authors: Atul Deodhar, MD
CME / ABIM MOC Released: 12/17/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/17/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for rheumatologists and other clinicians who manage patients with axial spondyloarthritis (axSpA), including orthopedists, orthopedic surgeons, physical medicine and rehabilitation (PM&R) specialists, primary care physicians, nurse practitioners (NPs), physician assistants (PAs), and chiropractors.

The goal of this activity is to update clinicians on the latest clinical data for managing and treating patients with axSpA.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical classification of radiographic and nonradiographic axSpA
- Clinical trial data of biologic therapies for axSpA
Demonstrate greater confidence in their ability to
- Select evidence-based treatment for patients with active axSpA

Disclosures

Faculty

Atul Deodhar, MD

Professor of Medicine
Medical Director
Rheumatology Clinics
Immunology Infusion Center
Oregon Health & Science University
Portland, Oregon

Disclosures

Disclosure: Atul Deodhar, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Amgen; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Galapagos; Gilead; Janssen; Lilly; Novartis; Pfizer; UCB Pharma
Served as a speaker or a member of a speakers bureau for: Janssen; Novartis; Pfizer; UCB Pharma
Received grants for clinical research from: AbbVie; Boehringer Ingelheim; Galapagos; Gilead; Lilly; Novartis; Pfizer; UCB Pharma

Editor

Karen Badal, MD, MPH

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Karen Badal, MD, MPH, has disclosed the following relevant financial relationships:
Owns stock, stock options or bonds from: Kallyope, Inc.

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Rheumatology

CME / ABIM MOC

What's New in Axial Spondyloarthritis?

Authors: Atul Deodhar, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/17/2020

Valid for credit through: 12/17/2021, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to update clinicians on the latest clinical data on managing and treating patients with axial spondyloarthritis (axSpA).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Full Live Event Audio

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Atul Deodhar, MD

Editor

Karen Badal, MD, MPH

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

CME / ABIM MOC

What's New in Axial Spondyloarthritis?

Target Audience and Goal Statement

Disclosures

Faculty

Atul Deodhar, MD

Editor

Karen Badal, MD, MPH

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

What's New in Axial Spondyloarthritis?

Educational Impact Challenge